

BIOGRAPHICAL SKETCH

NAME Ken Williams, PStat® (ASA)	POSITION TITLE Founder/Sr Biostatistician, KenAnCo Biostatistics
---	--

EDUCATION/TRAINING

INSTITUTION AND LOCATION	DEGREE	YEAR	FIELD OF STUDY
Georgia Tech, Atlanta GA	BS	1971	Applied Math
Troy State University, RAF Bentwaters UK	MS	1978	Management
Air Force Institute of Technology, Dayton OH	MS	1980	Operations Research
Air Command & Staff College, Montgomery AL		1985	Professional Military Education
American Statistical Assoc, San Antonio TX		1997	Logistic Regression Modeling
North Carolina State University, Raleigh NC		1998	Genetics for Statisticians
American Statistical Assoc, San Antonio TX		1999	Design & Analysis of Clinical Trials
American Statistical Assoc, Dallas TX		1999	Statistical Searches for Disease Genes
American Statistical Assoc, Baltimore MD		1999	Analysis of Correlated Data
American Statistical Assoc, Baltimore MD		1999	Cox Model for Correlated Events
American Statistical Assoc, San Antonio TX		2001	Mixed Models
American Statistical Assoc, San Antonio TX		2005	Fitting Tree Models Using R
American Statistical Assoc, San Antonio TX		2005	Applied Nonlinear Statistical Methods
Centers for Disease Control, Atlanta GA		2008	NHANES Survey Orientation Web Tutorial
Centers for Disease Control, Atlanta GA		2008	Preparing Analytical NHANES Datasets
American Statistical Assoc, San Antonio TX		2008	Bootstrap Methods and Permutation Tests
Conference of Texas Statisticians, Huntsville TX		2009	Bayesian Clinical Trials
International Chair on Cardiometabolic Risk		2009	New Frontiers in Diabetes Epidemiology
University Paris-Dauphine, San Antonio TX		2010	Computational Bayesian Statistics
Collaborative Institutional Training Initiative		2010	Human Biomedical Research
Inst. for Clinical Evaluative Sciences, Washington DC		2011	Advanced CVD Research Statistical Methods
University of Maryland, Silver Springs, MD		2011	Evaluating Prediction of Biomarkers & Tests
University of Maryland, Silver Springs, MD		2011	Absolute Risk Prediction
American Statistical Association, San Antonio TX		2012	Applied Mixed Models
South Central SAS Users Group, San Antonio TX		2013	Making the Most of Statistical Analysis
South Central SAS Users Group, San Antonio TX		2013	Techniques for Integrating SAS with Excel

A. POSITIONS AND HONORS**Professional Experience:**

1972-1994	United States Air Force Officer 1972-79 Computer systems 1980-94 Scientific Analysis: 1980-84 Promotions Analyst, AF Military Personnel Center, Randolph AFB, TX 1985-89 Assistant for Personnel Analysis, HQ Military Airlift Command, Scott AFB, IL 1989-90 Research Fellow, RAND Corporation, Santa Monica, CA 1990-94 Chief, Analysis Division, AF Military Personnel Center, Randolph AFB, TX
1996-2006	University of Texas Health Science Center at San Antonio, TX 1996-1999 Statistician, Clinical Epidemiology 1999-2004 Faculty Assoc Statistician, Clinical Epidemiology 2004-2006 Asst Professor/Research, Clinical Epidemiology 2005-2006 Director, Urology Center for Biostatistics and Epidemiology
2006-2007	Senior Business Modeling Analyst, Finance Department, Kinetic Concepts Inc
2007-	Founder/Sr Biostatistician, KenAnCo Biostatistics
2011-	Adjunct Asst Professor, Dept of Medicine, U TX Health Science Center at San Antonio

Honors: 2011 Certified as Professional Statistician by the American Statistical Association
 2005 Award for Outstanding Research in Epidemiology, Complications, or Prevention of Diabetes
 1980 Distinguished Graduate, AF Institute of Technology
 1978 Outstanding Data Automation Officer, US Air Forces Europe
 1968-1970 Dean's List, Georgia Tech,
 1967-1968 Dean's List, University of Georgia,
 1967 Rotary Scholastic Award, Willingham High School, Macon GA

Professional Organizations:

1997- American Statistical Assoc (Statistics in Epidemiology and Biometrics Sections)
 1999- American Diabetes Assoc (Epidemiology & Statistics Council)
 2000- European Association for the Study of Diabetes
 2004- International Diabetes Epidemiology Group
 2006-2007 American Urological Assoc
 2006-2007 Southwest Oncology Group
 2011- American Heart Association (Council on Epidemiology and Prevention)

B. PUBLICATIONS

1. Toth, P, Thanassoulis G, **Williams K**, Furberg C, Sniderman A. *The Risk-Benefit Paradigm vs the Causal Exposure Paradigm: LDL as a primary cause of vascular disease.* Journal of Clinical Lipidology. (2014) 8, 594-605.
2. Pencina MJ, Navar-Boggan AM, D'Agostino RB Sr, **Williams K**, Neely B, Sniderman A., Peterson ED. *Application of new cholesterol guidelines to a population-based sample.* New England Journal of Medicine. (2014) March 19. DOI: 10.1056
3. Navar-Boggan AM, Pencina MJ, **Williams K**, Sniderman A, Peterson ED. *Proportion of US adults potentially affected by the 2014 Hypertension Guideline.* Journal of the American Medical Association. (2014) March 29. DOI:10.1001
4. Thanassoulis G, **Williams K**, Ye K, Brook R, Couture P, Lawler P, deGraaf J, Furberg CD, Sniderman A. *relations of change in plasma levels of LDL-C, non-HDL-C and apoB with risk reduction from statin therapy: a meta-analysis of randomized trials.* Journal of the American Heart Association. (2014) March:e000759 DOI: 10.1161
5. Sniderman A, Thanassoulis G, Couture P, **Williams K**, Alam A, Furberg C. *Counterpoint: Statins do reduce fatal events.* Journal of Clinical Lipidology. (2013) July: 225–227
6. **Williams K**, Monroe H. *Cardiovascular disease risk prediction factors.* Journal of the American Medical Association. (2012) Nov: 308(19): 1969-70.
7. Abdul-Ghani M, **Williams K**, Kanat M, Altuntas Y, Defronzo R. *Insulin versus GLP-1 analogues in poorly controlled type 2 diabetic subjects on oral therapy A meta analysis.* Journal of Endocrinological Investigation. (2012) Apr.
8. Sniderman A, Thanassoulis G, Lawler P, **Williams K**, Furberg C. *Comparison of coronary calcium screening versus broad statin therapy for patients at intermediate cardiovascular risk.* American Journal of Cardiology. (2012) Aug 15: 110(4):530-533.
9. Lorenzo C, **Williams K**, Haffner SM. *Early and late insulin secretion during an oral glucose tolerance test and incident diabetes: The San Antonio Heart Study.* Diabetic Medicine . (2012) Aug 29(8):e151-8.
10. Sniderman A, Thanassoulis G, Couture P, **Williams K**, Alam A, Furberg C. *Is lower and lower better and better? A re-evaluation of the evidence from the Cholesterol Treatment Trialists' Collaboration meta-analysis for low-density lipoprotein lowering.* Journal of Clinical Lipidology. (2012) Jul-Aug: 6(4) 303-309.

11. Sniderman A, Lawler P, **Williams K**, Thanassoulis G, deGraaf J, Furberg C. *The causal exposure model of vascular disease.* Clinical Science. (2012) Apr 122(8):369-373.
12. White J, Cannon J, Stannard A, Burkhardt G, Spencer J, **Williams K**, Oh J, Rasmussen T. *Direct vascular control results in less physiologic derangement than proximal aortic clamping in a porcine model of noncompressible extrathoracic torso hemorrhage.* The Journal of Trauma. (2011) Nov; 71(5):1278-86; discussion 1286-7.
13. White J, Cannon J, Stannard A, Spencer J, Hancock H, **Williams K**, Oh J, Rasmussen T. *A porcine model for evaluating the management of noncompressible torso hemorrhage.* The Journal of Trauma. (2011) Jul:(1 Suppl):S131-8.
14. Sniderman A, **Williams K**, Contois J, Monroe H, McQueen M, deGraaf J, Furberg C. *A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk.* Circulation: Cardiovascular Quality and Outcomes. (2011) May 4:337-345.
15. DeFronzo RA, Tripathy D, Banerji MA, Bray GA, Buchanan TA, Clement S, Henry RR, Hodis HN, Kitabchi AE, Mack WJ, Mudaliar S, Ratner R, Schwenke DC, **Williams K**, Stentz FB, Musi N, Reaven PD. *Pioglitazone reduces conversion of IGT to diabetes: Results from Actos Now for Prevention of Diabetes (ACT NOW) Study.* New England Journal of Medicine. 2011 March; 364:1104-1115.
16. Hancock H, Sannard A, Burkhardt G, **Williams K**, Dixon , Cowart J, Spencer J, Rasmussen T. *Hemorrhagic shock worsens neuromuscular recovery in a porcine model of hind limb vascular injury and ischemia reperfusion.* Journal of Vascular Surgery. Official publication, The Society for Vascular Surgery and International Society for Cardiovascular Surgery, North American Chapter. (2011) Jan: 53(4):1052-62.
17. Sniderman A, **Williams K**, de Graaf J. *Non-HDL C equals apolipoprotein B: except when it does not!* Current Opinion in Lipidology. (2010) Dec: (21(6):518-24.
18. Burkhardt G, Gifford S, Propper B, Spencer J, **Williams K**, Jones L, Sumner N, Cowart J, Rasmussen T. *The impact of ischemic intervals on neuromuscular recovery in a porcine (sus scrofa) survival model of extremity vascular injury.* Journal of Vascular Surgery. Official publication, The Society for Vascular Surgery and International Society for Cardiovascular Surgery, North American Chapter. (2010) Oct:53(!):165-73.
19. Burkhardt G, Cox M, Clouse WD, Porras C, Gifford S, **Williams K**, Propper B, Rasmussen T. *Outcomes of selective tibial artery repair following combat-related extremity injury.* Journal of Vascular Surgery. Official publication, The Society for Vascular Surgery and International Society for Cardiovascular Surgery, North American Chapter.(2010)Jul:52(1)91-6.
20. Sniderman A, McQueen M, Contois J, **Williams K**, Furberg C. *Why is non-high-density lipoprotein cholesterol a better marker of the risk of vascular disease than low-density lipoprotein cholesterol?* Journal of Clinical Lipidology. (2010) May-Jun 4(3)152-155.
21. Sniderman A, Williams K, McQueen M, Contois J, Furberg C. *When is equal not equal?* Journal of Clinical Lipidology, (2010) March-April; 4(2):83-88
22. Sniderman A, Solhpour A, Alam A, **Williams K**, Sloan JA. *Cardiovascular death in dialysis patients: lessons we can learn from AURORA.* Clinical Journal of The American Society of Nephrology. (2010) Feb: 5(2):P335-40.
23. Sniderman AD, deGraaf J, Couture P, **Williams K**, Kiss RS, Watts GF. *Regulation of plasma LDL; the apoB paradigm.* Clinical Science, (2010) Mar: 118(5):333-339. (Printed in Great Britain).

24. Burdhardt G, Gifford S, Propper B, Spencer J, **Williams K**, Jones L, Sumner N, Cowart J, Rasmussen T. *Surgical restoration of flow following prolonged ischemia inhibits neuromuscular recovery in a porcine (sus scrofa) model of extremity vascular injury.* Journal of Vascular Surgery. (2010) Jan: 51(6).
25. Solhpour A., Parkhideh S, Sarrafzadegan N, Asgary S, **Williams K**, Jungner I, Aastveit A, Walldius G, Sniderman A. *Levels of Lipids and Apolipoproteins in Three Cultures.* Atherosclerosis, (2009) Nov 207(1)200-207.
26. Lorenzo C, **Williams K**, Stern MP, Haffner SM. *Height, ethnicity, and the incidence of diabetes: The San Antonio Heart Study.* Metabolism: Clinical and Experimental, (2009) Nov 58 (11):1530-1535.
27. Sniderman A, **Williams K**, Cobbaert C. *ApoB versus non-HDL-C: what to do when they disagree.* Current Atherosclerosis Reports. (2009) Sep 11(5):358-63.
28. Jiménez-Corona A, López-Ridaura R, **Williams K**, González-Villalpando ME, Simón J, González-Villalpando C. *Applicability of Framingham risk equations for studying a low-income Mexican population.* Salud Pública de México, (2009) July-August; 51(4):298-305.
29. Fowler S, Stern M, **Williams K**, Hazuda H, Hunt K, Resendez R. *Response to "letter to fowler et al. 2008.* Obesity. (2009) May:17(4):628-9.
30. **Williams K**, Hunt KJ, Tchernof A, Wagenknecht LE, Haffner SM, Sniderman AD. *Diabetes, abdominal adiposity, and atherogenic dyslipoproteinemia in women compared to men.* Diabetes, (2008) Dec; 57:3289-3296.
31. Fowler SP, **Williams K**, Resendez RG, Hunt KJ, Hazuda HP, Stern MP. *Fueling the obesity epidemic? Artificially sweetened beverage use and long-term weight gain.* Obesity, (2008) Aug; 16(8):1894-1900.
32. Festa A, **Williams K**, Hanley AJ, Haffner SM. *Beta-cell dysfunction in subjects with impaired glucose tolerance and early type 2 diabetes: comparison of surrogate markers with first-phase secretion from an intravenous glucose tolerance test.* Diabetes, (2008) Jun; 57(6):1638-44.
33. Stern M, **Williams K**, Eddy D, Kahn R. *Validation of prediction of diabetes by the Archimedes model and comparison with other predicting models.* Diabetes Care. (2008) Jun; 31(*):1670-1.
34. Hunt KJ, **Williams K**, Hazuda HP, Stern MP, Haffner SM. *The Metabolic Syndrome and the Impact of Diabetes on coronary Heart Disease Mortality in Women and Men: The San Antonio Heart Study.* Annals of Epidemiology, (2007) Nov; 17(11):870-7.
35. Abdul-Ghani MA, **Williams K**, DeFronzo RA, Stern MP. *What is the Best Predictor of Future Type 2 Diabetes?* Diabetes Care, (2007) June 30(6):1544-1548.
36. Lorenzo C, Serrano-Rios M, Martinez-Larrad MT, Gonzalez-Villalpando C, **Williams K**, Gabriel R, Stern MP, Haffner SM. *Which obesity index best explains prevalence differences in type 2 diabetes mellitus?* Obesity, (2007) May; 15(5):1294-301.
37. Lorenzo C, **Williams K**, Hunt KJ, Haffner SM. *The National Cholesterol Education Program – Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes.* Diabetes Care, (2007) Jan; 30(1):8-13.
38. Nannipieri M, Posadas R, Bonotti A, **Williams K**, Gonzalez-Villalpando C, Stern MP, Ferrannini E. *Polymorphism of the 3' - untranslated region of the leptin receptor gene, but not the adiponectin SNP45 polymorphism, predicts type 2 diabetes: a population-based study.* Diabetes Care. (2006) Nov; 29(11): 2509-11.
39. Abdul-Ghani M, **Williams K**, DeFronzo R, Stern M. *Risk of progression to type 2 diabetes based on relationship between postload plasma glucose and fasting plasma glucose.* Diabetes Care. (2006)Aug;29(7):1613-8.

40. Festa A, **Williams K**, D'Agostino R Jr, Wagenknecht LE, Haffner SM. *The natural course of beta-cell function in nondiabetic and diabetic individuals: the Insulin Resistance Atherosclerosis study.* Diabetes, (2006) Apr; 55(4):1114-20.
41. Lorenzo C, **Williams K**, Hunt KJ, Haffner SM. *Trend in the prevalence of the metabolic syndrome and its impact on cardiovascular disease incidence: the San Antonio Heart Study.* Diabetes Care, (2006) Mar; 29(3):625-30.
42. Festa A, **Williams K**, Tracy RP, Wagenknecht LE, Haffner SM. *Progression of plasminogen activator inhibitor-1 and fibrinogen levels in relation to incident type 2 diabetes.* Circulation, (2006) Apr; 113(14):1753-1759.
43. Festa A, **Williams K**, D'Agostino R, Wagenknecht LE, Haffner SM. *The natural course of beta-cell function in nondiabetic and diabetic individuals: the Insulin Resistance Atherosclerosis Study.* Diabetes, (2006) Apr; 55(4):1114-1120
44. Lorenzo C, **Williams K**, Hunt KJ, Haffner SM. *Trend in the prevalence of the metabolic syndrome and its impact on cardiovascular disease incidence: the San Antonio Heart Study.* Diabetes Care, (2006) Mar; 29(3):625-630.
45. Barter PJ, Ballantyne CM, Carmena R, Castro-Cabezas M, Chapman MJ, Couture P, de Graaf, J, Durrington PN, Faergeman O, Frohlich J, Reddy KS, Rosenson R, Sarrafadegan N, Sniderman A, Stalenhoef AF, Stein E, Talmud PJ, TonkinAM, Walldius, G, **Williams K**. *ApoB versus cholesterol in estimating cardiovascular risk and inguiding therapy: report of the thirty-person/ten-country panel.* Journal of Internal Medicine. (2006) Mar; 259(3):247-58.
46. Lorenzo C, Serrano-Ríos M, Martínez-Larrad MT, González-Sánchez JL, Seclén S, Villena A, Gonzalez-Villalpando C, **Williams K**, Haffner SM. *Geographic variations of the International Diabetes Federation and the National Cholesterol Education Program-Adult Treatment Panel III definitions of the metabolic syndrome in nondiabetic subjects.* Diabetes Care, (2006) Mar; 29(3):685-691
47. Hanley AJ, Karter AJ, **Williams K**, Festa A, D'Agostino RB, Wagenknecht LE, Haffner SM. *Prediction of type 2 diabetes mellitus with alternative definitions of the metabolic syndrome: the Insulin Resistance Atherosclerosis Study.* Circulation, (2005) Dec;112(24):3713-3721
48. Hanley AJ, **Williams K**, Festa A, Wagenknecht LE, D'Agostino RB, Haffner SM. *Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study.* Diabetes, (2005) Nov; 54(11):3140-3147.
49. Lorenzo C. **Williams K**. Gonzalez-Villalpando C. Steven Haffner SM. *The Prevalence of the Metabolic Syndrome did not Increase in Mexico City between 1990-1992 and 1997-1999 Despite More Central Obesity.* Diabetes Care, (2005) Aug.
50. Corona AJ, Martinez DR, Avila MH, Haffner S, **Williams K**, González Villalpando ME, Simon J, Stern M, Gonzalez-Villalpando C. *Microalbuminuria as a predictor of myocardial infarction in a Mexican population: the Mexico City Diabetes Study.* Kidney International Supplement (2005) Aug;(97):34-39
51. Nannipieri M, Gonzales C, Baldi S, Posadas R, **Williams K**, Haffner SM, Stern MP, Ferrannini E. *Liver enzymes, the metabolic syndrome, and incident diabetes: the Mexico City diabetes study.* Diabetes Care, (2005) Jul; 28(7):1757-1762.
52. Hanley AJ, Meigs JB, **Williams K**, Haffner SM, D'Agostino RB. *Re: (Mis)use of Factor Analysis in the Study of Insulin Resistance Syndrome.* American Journal of Epidemiology, (2005) Jun; 161(12):1182-1184.
53. Festa A, **Williams K**, Hanley AJ, Otvos JD, Goff DC, Wagenknecht LE, Haffner SM. *Nuclear magnetic resonance lipoprotein abnormalities in prediabetic subjects in the Insulin Resistance Atherosclerosis Study.* Circulation, (2005) Jun; 111(25):3465-3472.

54. Stern MP, **Williams K**, Hunt KJ. *Impact of diabetes/metabolic syndrome in patients with established cardiovascular disease.* Atherosclerosis Supplement, (2005) May; 6(2):3-6.
55. Lorenzo C, **Williams K**, Gonzalez-Villalpando C, Stern MP, Hazuda HP, Haffner SM. *Lower hypertension risk in Mexico City than in San Antonio.* American Journal of Hypertension, (2005) Mar;18(3):385-391.
56. Stern SE, **Williams K**, Ferrannini E, DeFronzo RA, Bogardus C, Stern MP. *Identification of individuals with insulin resistance using routine clinical measurements.* Diabetes, (2005) Feb;54(2):333-339.
57. Sattar N, **Williams K**, Sniderman AD, D'Agostino R, Haffner SM. *Comparison of the associations of apolipoprotein B and non-high-density lipoprotein cholesterol with other cardiovascular risk factors in patients with the metabolic syndrome in the Insulin Resistance Atherosclerosis Study.* Circulation, (2004) Oct;110(17):2687-2693.
58. Hunt KJ, Resendez R, **Williams K**, Haffner S, Stern M. *National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study.* Circulation, (2004) Oct; 110(10):1251-7.
59. Hanley AJ, **Williams K**, Festa A, Wagenknecht LE, D'Agostino RB, Kempf J, Zinman B, Haffner SM. *Elevations in markers of liver injury and risk of type 2 diabetes: the insulin resistance atherosclerosis study.* Diabetes (2004) Oct;53(10):2623-2632.
60. **Williams K**, Stern MP, Gonzalez-Villalpando C. *Secular trends in obesity in Mexico City and in San Antonio.* Nutrition Reviews, 2004 Jul;62(7/2):S158-S162.
61. Meigs JB, **Williams K**, Sullivan LM, Hunt KJ, Haffner SM, Stern MP, González Villalpando C, Perhanidis JS, Nathan DM, D'Agostino RB, D'Agostino RB, Wilson PW. *Using metabolic syndrome traits for efficient detection of impaired glucose tolerance.* Diabetes Care, (2004) Jun;27(6):1417-1426.
62. Sniderman A, **Williams K**, Haffner S, Sattar N. *Insights from apoB: from better diagnosis & therapy to the Medusa Hypothesis.* Atherosclerosis Supplement, (2004) May;5(2):19-24.
63. Ferrannini E, Nannipieri M, **Williams K**, Gonzales C, Haffner SM, Stern MP. *Mode of onset of type 2 diabetes from normal or impaired glucose tolerance.* Diabetes, (2004) Jan;53(1):160-165.
64. Stern MP, **Williams K**, Villalpando C, Hunt KJ, Haffner SM. *Does the Metabolic Syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease?* Diabetes Care, (2004); 27:2676-2681.
65. Lorenzo C, Serrano-Ríos M, Martínez-Larrad MT, Gabriel R, **Williams K**, Gómez-Gerique JA, Stern MP, Haffner SM. *Central adiposity determines prevalence differences of the metabolic syndrome.* Obesity Research, (2003) Dec;11(12):1480-1487.
66. North KE, **Williams K**, Williams JT, Best LG, Lee ET, Fabsitz RR, Howard BV, Gray R, MacCluer JW. *Evidence for genetic factors underlying the Insulin Resistance Syndrome in American Indians.* Obesity Research, (2003) Dec;11(12):1444-1448.
67. Hunt KJ, Resendez RG, **Williams K**, Haffner SM, Stern MP, Hazuda HP. *All-cause and cardiovascular mortality among Mexican-American and non-Hispanic White older participants in the San Antonio Heart Study- evidence against the "Hispanic paradox".* American Journal of Epidemiology, (2003) Dec; 158(11): 1048-1057.
68. **Williams K**, Sniderman AD, Sattar N, D'Agostino R, Wagenknecht LE, Haffner SM. *Comparison of the associations of apolipoprotein B and low-density lipoprotein cholesterol with other cardiovascular risk factors in the Insulin Resistance Atherosclerosis Study (IRAS).* Circulation, (2003) Nov;108(19):2312-2316.

69. Lorenzo C, Okoloise M, **Williams K**, Stern MP, Haffner SM. *The metabolic syndrome as predictor of type 2 diabetes: the San Antonio Heart Study.* Diabetes Care, (2003) Nov;26(11):3153-3159.
70. Hunt KJ, **Williams K**, Rivera D, O'Leary DH, Haffner SM, Stern MP, González Villalpando C. *Elevated carotid artery intima-media thickness levels in individuals who subsequently develop type 2 diabetes.* Arteriosclerosis, Thrombosis, and Vascular Biology, (2003) Oct;23(10):1845-1850.
71. Meigs JB, Wilson PW, Nathan DM, D'Agostino RB, **Williams K**, Haffner SM. *Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring Studies.* Diabetes, (2003) Aug;52(8):2160-2167.
72. Del Rincón I, **Williams K**, Stern MP, Freeman GL, O'Leary DH, Escalante A. *Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects.* Arthritis and Rheumatism, (2003) Jul;48(7):1833-1840.
73. Burke JP, **Williams K**, Narayan KM, Leibson C, Haffner SM, Stern MP. *A population perspective on diabetes prevention: whom should we target for preventing weight gain?* Diabetes Care, (2003) Jul;26(7):1999-2004.
74. Nannipieri M, Posadas R, **Williams K**, Politi E, Gonzales-Villalpando, Stern MP, Ferrannini E. *Association between polymorphisms of the atrial natriuretic peptide gene and proteinuria: a population-based study.* Diabetologia, (2003) Apr; 46(3):429-32.
75. Stern MP, **Williams K**, Haffner SM. *Do we need the oral glucose tolerance test to identify future cases of type 2 diabetes?* Diabetes Care, (2003) Mar;26(3):940-941.
76. Hanley AJ, **Williams K**, Gonzalez C, D'Agostino RB, Wagenknecht LE, Stern MP, Haffner SM. *Prediction of type 2 diabetes using simple measures of insulin resistance: combined results from the San Antonio Heart Study, the Mexico City Diabetes Study, and the Insulin Resistance Atherosclerosis Study.* Diabetes, (2003) Feb;52(2):463-469.
77. Gonzalez-Villalpando C, Rivera-Martinez D, Cisneos-Castolo M, Gonzalez-Villalpando MaE, Simon J, **Williams K**, Haffner S, Stern M. *Seven-year incidence and progression of obesity. Characterization of body fat pattern evolution in low-income Mexico City urban population.* Archives of Medical Research, (2003) Jan; 34(4):348-53
78. Sattar N, **Williams K**, Han TS, Gonzalez-Villalpando C, Lean MJ, Haffner S. *Prospective relation of C-reactive protein with type 2 diabetes: response to Snider et al.* Diabetes Care, (2003) Jan; 26(5):1657-1658.
79. Han TS, Sattar N, **Williams K**, Gonzalez-Villalpando C, Lean ME, Haffner SM. *Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study.* Diabetes Care, (2002) Nov;25(11):2016-2021.
80. Stern MP, **Williams K**, Haffner SM. *Optimal prediction of diabetes.* Annals of Internal Medicine, (2002) Nov;137(10):856.
81. Stern MP, Fatehi P, **Williams K**, Haffner SM. *Predicting future cardiovascular disease: do we need the oral glucose tolerance test?* Diabetes Care, (2002) Oct;25(10):1851-1856.
82. Hunt KJ, **Williams K**, Resendez RG, Hazuda HP, Haffner SM, Stern MP. *All-cause and cardiovascular mortality among diabetic participants in the San Antonio Heart Study: evidence against the "Hispanic Paradox".* Diabetes Care, (2002) Sep;25(9):1557-1563.
83. Han TS, **Williams K**, Sattar N, Hunt KJ, Lean ME, Haffner SM. *Analysis of obesity and hyperinsulinemia in the development of metabolic syndrome: San Antonio Heart Study.* Obesity Research, (2002) Sep;10(9):923-931.
84. Haffner SM, Greenberg AS, Weston WM, Chen H, **Williams K**, Freed MI. *Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.* Circulation, (2002) Aug;106(6):679-684.

85. Duggirala R, Uttley M, **Williams K**, Arya R, Blangero J, Crawford MH. *Genetic determination of biological age in the Mennonites of the Midwestern United States.* Genetic Epidemiology, (2002) Aug;23(2):97-109.
86. Hanley AJ, **Williams K**, Stern MP, Haffner SM. *Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study.* Diabetes Care, (2002) Jul;25(7):1177-1184.
87. Stern MP, **Williams K**, Haffner SM. *Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test?* Annals of Internal Medicine, (2002) Apr;136(8):575-581.
88. Arya R, Blangero J, **Williams K**, Almasy L, Dyer TD, Leach RJ, O'Connell P, Stern MP, Duggirala R. *Factors of insulin resistance syndrome--related phenotypes are linked to genetic locations on chromosomes 6 and 7 in nondiabetic Mexican-Americans.* Diabetes, (2002) Mar;51(3):841-847.
89. Arya R, Duggirala R, Almasy L, Rainwater D, Mahaney M, Cole S, Dyer T, **Williams K**, Leach R, Hixson J, MacCluer J, O'Connell P, Stern M, Blangero J. *Linkage of high-density lipoprotein cholesterol concentrations to a locus on chromosome 9p in Mexican Americans.* Nature Genetics, (2002) Feb;30(1):102-5.
90. Lorenzo C, Serrano-Rios M, Martinez-Larrad MT, Gabriel R, **Williams K**, Gonzalez-Villalpando C, Stern MP, Hazuda HP, Haffner S. *Prevalence of hypertension in Hispanic and non-Hispanic white populations.* Hypertension, (2002) Feb;39(2):203-208.
91. Del Rincón ID, **Williams K**, Stern MP, Freeman GL, Escalante A. *High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors.* Arthritis and Rheumatism, (2001) Dec;44(12):2737-2745.
92. Lorenzo C, Serrano-Rios M, Martinez-Larrad MT, Gabriel R, **Williams K**, Gonzalez-Villalpando C, Stern MP, Hazuda HP, Haffner SM. *Was the historic contribution of Spain to Mexican gene pool partially responsible for higher prevalence of type 2 diabetes in Mexican-origin populations? Spanish Insulin Resistance, San Antonio Heart, and Mexico City Diabetes.* Diabetes Care, (2001) Dec;24(12):2059-2064.
93. Festa A, D'Agostino R, **Williams K**, Karter AJ, Mayer-Davis EJ, Tracy RP, Haffner SM. *The relation of body fat mass and distribution to markers of chronic inflammation.* International Journal of Obesity and Related Metabolic Disorders, (2001) Oct;25(10):1407-1415.
94. Burke JP, **Williams K**, Haffner SM, Villalpando CG, Stern MP. *Elevated incidence of type 2 diabetes in San Antonio, Texas, compared with that of Mexico City, Mexico.* Diabetes Care, (2001) Sep;24(9):1573-1578.
95. Duggirala R, Blangero J, Almasy L, Arya R, Dyer TD, **Williams KL**, Leach RJ, O'Connell P, Stern MP. *A major locus for fasting insulin concentrations and insulin resistance on chromosome 6q with strong pleiotropic effects on obesity-related phenotypes in nondiabetic Mexican Americans.* American Journal of Human Genetics, (2001) May;68(5):1149-1164.
96. Mangano A, Gonzalez E, Dhanda R, Catano G, Bamshad M, Bock A, Duggirala R, **Williams K**, Mummidi S, Clark RA, Ahuja SS, Dolan MJ, Bologna R, Sen L, Ahuja SK. *Concordance between the CC chemokine receptor 5 genetic determinants that alter risks of transmission and disease progression in children exposed perinatally to human immunodeficiency virus.* Journal of Infectious Diseases, 183:1574-1585.
97. Duggirala R, Blangero J, Almasy L, Dyer TD, **Williams KL**, Leach RJ, O'Connell P, Stern MP. *A major susceptibility locus influencing plasma triglyceride concentrations is located on chromosome 15q in Mexican Americans.* American Journal of Human Genetics, (2000) Apr;66(4):1237-1245.

98. Burke JP, **Williams K**, Gaskill SP, Hazuda HP, Haffner SM, Stern MP. *Rapid rise in the incidence of type 2 diabetes from 1987 to 1996: results from the San Antonio Heart Study.* Archives of Internal Medicine, (1999) Jul;159(13):1450-1456.
99. Wooten EC, Fults D, Duggirala R, **Williams K**, Kyritsis AP, Bondy ML, Levin VA, O'Connell P. *A study of loss of heterozygosity at 70 loci in anaplastic astrocytoma and glioblastoma multiforme with implications for tumor evolution.* Neuro-oncology, (1999) Jul;1(3):169-176.
100. Duggirala R, Blangero J, Almasy L, Dyer TD, **Williams KL**, Leach RJ, O'Connell P, Stern MP. *Linkage of type 2 diabetes mellitus and of age at onset to a genetic location on chromosome 10q in Mexican Americans.* American Journal of Human Genetics, (1999) Apr;64(4):1127-1140.
101. Saric T, Brkanac Z, Troyer DA, Padalecki SS, Sarosdy M, **Williams K**, Abadesco L, Leach RJ, O'Connell P, Williams KL. *Genetic pattern of prostate cancer progression.* International Journal of Cancer, (1999) Apr;81(2):219-224.
102. Burke JP, Haffner SM, Gaskill SP, **Williams K**, Stern MP. *Reversion from type 2 diabetes to nondiabetic status. Influence of the 1997 American Diabetes Association criteria.* Diabetes Care, (1998) Aug;21(8):1266-1270.